NEW YORK (GenomeWeb News) – Verdezyne said that it will optimize selected genes that encode industrial enzymes for Novozymes, under a contract announced today.

Verdezyne, the Carlsbad, Calif.-based firm that was formerly called Coda Genomics, uses computational methods to design and synthesize gene libraries for engineering proteins, metabolic pathways, and microorganisms. Its technologies are used to optimize commercial fermentation processes, which are applied to manufacturing platform chemicals and biofuels.

Terms of the contract were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.